Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eisai, Purdue To File Insomnia Drug Following Positive Head-To-Head

Executive Summary

Eisai and its partner Purdue are expected to file insomnia drug lemborexant with the US FDA within the next 12 months, following more positive data.

You may also be interested in...



Asia Deal Watch: Takeda Licenses Curadev STING Agonist To Further Its IO Ambitions

The Japanese pharma, continuing to bolster its pipeline after buying Shire, is partnering with Skyhawk in neurodegenerative diseases under another new deal. Also, Purdue cites shifting business priorities for a decision to end Eisai collaboration on sleep disorder drug.

Keeping Track: FDA's Review Actions Carry On During Shutdown

The latest drug development news and highlights from our US FDA Performance Tracker.

Priority Review Voucher Crash: Spark's Sale To Jazz Lowest Price Since 2014

Only the first publicly disclosed sale of a priority review voucher was lower than what Jazz Pharmaceuticals paid Spark Therapeutics for its coupon.

Topics

Related Companies

UsernamePublicRestriction

Register

SC100538

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel